-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Veracyte, Raises Price Target to $65

Benzinga·09/09/2026 18:01:31
語音播報
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.